Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. - Arellano ML; Thirman MJ; DiPersio JF; Heiblig M; Stein EM; Schuh AC; Žučenka A; de Botton S; Grove CS; Mannis GN; Papayannidis C; Perl AE; et al. (Blood, 2025)